Vav1 inhibits RANKL-induced osteoclast differentiation and bone resorption
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vav1 is a Rho/Rac guanine nucleotide exchange factor primarily expressed in hematopoietic cells. In this study, we investigated the potential role of Vav1 in osteoclast (OC) differentiation by comparing the ability of bone marrow mononuclear cells (BMMCs) obtained from Vav1-deficient (Vav1−/−) and wild-type (WT) mice to differentiate into mature OCs upon stimulation with macrophage colony stimulating factor and receptor activator of nuclear kappa B ligand in vitro. Our results suggested that Vav1 deficiency promoted the differentiation of BMMCs into OCs, as indicated by the increased expression of tartrate-resistant acid phosphatase, cathepsin K, and calcitonin receptor. Therefore, Vav1 may play a negative role in OC differentiation. This hypothesis was supported by the observation of more OCs in the femurs of Vav1−/− mice than in WT mice. Furthermore, the bone status of Vav1−/− mice was analyzed in situ and the femurs of Vav1−/− mice appeared abnormal, with poor bone density and fewer number of trabeculae. In addition, Vav1-deficient OCs showed stronger adhesion to vitronectin, an v3 integrin ligand important in bone resorption. Thus, Vav1 may inhibit OC differentiation and protect against bone resorption.
Abstract
Vav1 is a Rho/Rac guanine nucleotide exchange factor primarily expressed in hematopoietic cells. In this study, we investigated the potential role of Vav1 in osteoclast (OC) differentiation by comparing the ability of bone marrow mononuclear cells (BMMCs) obtained from Vav1-deficient (Vav1−/−) and wild-type (WT) mice to differentiate into mature OCs upon stimulation with macrophage colony stimulating factor and receptor activator of nuclear kappa B ligand in vitro. Our results suggested that Vav1 deficiency promoted the differentiation of BMMCs into OCs, as indicated by the increased expression of tartrate-resistant acid phosphatase, cathepsin K, and calcitonin receptor. Therefore, Vav1 may play a negative role in OC differentiation. This hypothesis was supported by the observation of more OCs in the femurs of Vav1−/− mice than in WT mice. Furthermore, the bone status of Vav1−/− mice was analyzed in situ and the femurs of Vav1−/− mice appeared abnormal, with poor bone density and fewer number of trabeculae. In addition, Vav1-deficient OCs showed stronger adhesion to vitronectin, an v3 integrin ligand important in bone resorption. Thus, Vav1 may inhibit OC differentiation and protect against bone resorption.
참고문헌 (37)
- Katzav S, "vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells", EMBO J, 8, pp.2283~2290 (1989)
- Gakidis MA, "Vav GEFs are required for 2 integrin-dependent functions of neutrophils", J Cell Biol, 166, pp.273~282 (2004)
- Krawczyk C, "Vav1 controls integrin clustering and MHC", peptidespecific cell adhesion to antigen-presenting cells, 2002, pp.16, 331~343
- Turner M, "VAV proteins as signal integrators for multi-subunit immune-recognition receptors", Nat Rev Immunol, 2, pp.476~486 (2002)
- Pearce AC, "Vav family proteins are required for optimal regulation of PLCγ2 by integrin αIIbβ3", Biochem J, 401, pp.753~761 (2007)
- Garcia-Bernal D, "Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin α4β1", Mol Biol Cell, 16, pp.3223~3235 (2005)
- del Pozo MA, "Guanine exchange-dependent and-independent effects of Vav1 on integrin-induced T cell spreading", J Immunol, 170, pp.41~47 (2003)
- Spurrell DR, "Vav1 regulates the migration and adhesion of dendritic cells", J Immunol, 183, pp.310~318 (2009)
- Manolagas SC, "Birth and death of bone cells : basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis", Endocr Rev, 21, pp.115~137 (2000)
- 고정민, "Osteoclast-derived SLIT3 is a coupling factor linking bone resorption to bone formation", BMB Reports, 51(6), pp.263~264 (2018), 생화학분자생물학회
- Roodman GD, "Advances in bone biology : the osteoclast", Endocr Rev, 17, pp.308~332 (1996)
- Athanasou NA, "Cellular biology of bone-resorbing cells", J Bone Joint Surg Am, 78, pp.1096~1112 (1996)
- Vaananen HK, "Osteoclast lineage and function", Arch Biochem Biophys, 473, pp.132~138 (2008)
- Holtrop ME, "The ultrastructure of the osteoclast and its functional implications", Clin Orthop Relat Res, 123, pp.177~196 (1977)
- Nesbitt S, "Biochemical characterization of human osteoclast integrins. Osteoclasts express αvβ3, α2β1, and αvβ1 integrins", J Biol Chem, 268, pp.16737~16745 (1993)
- Mellis DJ, "The skeleton : a multi-functional complex organ : the role of key signalling pathways in osteoclast differentiation and in bone resorption", J Endocrinol, 211, pp.131~143 (2011)
- Faccio R, "Vav3 regulates osteoclast function and bone mass", Nat Med, 11, pp.284~290 (2005)
- Saftig P, "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice", Proc Natl Acad Sci, 95, pp.13453~13458 (1998)
- Hattersley G, "Calcitonin receptors as markers for osteoclastic differentiation : correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures", Endocrinol, 125, pp.1606~1612 (1989)
- Perilli E, "Dependence of mechanical compressive strength on local variations in microarchitecture in cancellous bone of proximal human femur", J Biomech, 41, pp.438~446 (2008)
- Hotokezaka H, "U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264. 7 cells into osteoclast-like cells", J Biol Chem, 277, pp.47366~47372 (2002)
- Li X, "p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function", Endocrinol, 143, pp.3105~3113 (2002)
- Matsumoto M, "Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand(RANKL)", J Biol Chem, 275, pp.31155~31161 (2000)
- Boyle WJ, "Osteoclast differentiation and activation", Nature, 423, pp.337~342 (2003)
- Walsh MC, "Osteoimmunology : interplay between the immune system and bone metabolism", Annu Rev Immunol, 24, pp.33~63 (2006)
- Tybulewicz VL, "Vav1 : a key signal transducer downstream of the TCR", Immunol Rev, 192, pp.42~52 (2003)
- Movilla N, "How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42", Oncogene, 20, pp.8057~8065 (2001)
- Lee NK, "Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-κB activation", Mol Cell Biochem, 281, pp.55~61 (2006)
- Movilla N, "Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins", Mol Cell Biol, 19, pp.7870~7885 (1999)
- Wang Y, "Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis", J Bone Miner Res, 23, pp.260~270 (2008)
- Roberts AW, "Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense", Immunity, 10, pp.183~196 (1999)
- Huang S, "The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts", Bone, 60, pp.235~245 (2013)
- Bustelo XR, "Vav proteins, adaptors and cell signaling", Oncogene, 20, pp.6372~6381 (2001)
- Fischer KD, "Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor", Curr Biol, 8, pp.554~562 (1998)
- Kang IS, "NADPH oxidase gp91phox contributes to RANKL-induced osteoclast differentiation by upregulating NFATc1", Sci Rep, 6, pp.38014~ (2016)
- Bouxsein ML, "Guidelines for assessment of bone microstructure in rodents using micro-computed tomography", J Bone Miner Res, 25, pp.1468~1486 (2010)
- Kim C, "Rac2 is an essential regulator of neutrophil nicotinamide adenine dinucleotide phosphate oxidase activation in response to specific signaling pathways", J Immunol, 166, pp.1223~1232 (2001)